News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Bayer will be setting up 27 telemedicine centres in 12 districts across 8 states with implementing partners Telerad RxDx and Piramal Swasthya
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
Subscribe To Our Newsletter & Stay Updated
